EPOgen and Restrictive Transfusions in Patients Undergoing Cardiac Surgery (EPORT)

Stopped early · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Cardiac Surgery-CABG, Cardiac Valve Replacement

In brief

Key facts

Study ID: NCT02802592
Run by: Johns Hopkins University
People needed: 4
Starts: 2015-05-01
Expected to finish: 2017-02-27
Last updated by the study team: 2019-02-26

Who can join

Age: 18 and older, up to 64. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Be male or female and 18 years of age or older, but less than 65 years of age
Be willing to performed written informed consent prior to study initiation
Be willing and able to comply with the protocol for study duration
Be scheduled to undergo elective cardiac surgery requiring CPB and including: coronary artery bypass graft (CABG), aortic, mitral, or tricuspid valve replacement or repair, replacement of more than one cardiac valve, or CABG with combined cardiac valve replacement or repair.

You may not qualify if…

Over the age of 64 years
Patients who receive allogeneic transfusion 60 days prior to surgery
Hgb > 15g/dl
Patients who are pregnant or currently lactating
Women of childbearing potential (e.g. those not surgically sterilized or not post-menopausal) must use 2 methods of contraception including at least one barrier method.
End-stage renal disease requiring renal replacement therapy or dialysis
Hepatic dysfunction (defined as total bilirubin value > 1.5 mg/dl)
Off-pump (no CPB) cardiac surgery
Emergency surgical procedure
Inability to receive blood products
Endocarditis as defined my Modified Duke Criteria
Any congenital coagulation disorder
Chronic anemia (defined as preoperative Hgb concentration < 10 g/dl)
Low platelet count (defined as preoperative platelet count less than 150 x 103/μl)
Not a surgical candidate due to high risk of morbidity or mortality
Surgery for aneurysm repair, dissection, or other thoracic aortic procedure
Congenital heart surgery
Cardiogenic shock or hemodynamic instability within 24 hours prior to surgery, as defined by systolic blood pressure < 80 mmHg and heart rate > 120 beats per minute
Known malignancy within the past 5 years
Life expectancy < 12 months
Current active infection requiring antibiotic treatment
Inability to comply with study protocol
Contraindication to Epogen
Hypersensitivity to epoetin or any component of the formulation
Pure red cell aplasia (due to epoetin or other epoetin protein drugs)

Where it is running

Suburban Hospital — Bethesda, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.